{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:13:07Z","timestamp":1791072787402,"version":"4.1.0"},"reference-count":38,"publisher":"Georg Thieme Verlag KG","issue":"06","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tierarztl Prax Ausg K"],"published-print":{"date-parts":[[2016]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Gegenstand und Ziel: Melittin, Hauptbestandteil des Bienengifts, hemmt in vitro die Replikation des humanen Immunschwachevirus. Es ist in vivo nicht toxisch fur Katzen. Ziel der Studie war die Untersuchung der Wirksamkeit von Melittin bei Katzen mit naturlicher Infektion mit dem felinen Immunschwachevirus (FIV). Material und Methoden: In einer prospektiven, randomisierten Doppelblindstudie wurden 20 Katzen mit Melittin (500 \u03bcg\/kg, 10 Katzen) oder Plazebo (phosphatgepufferte Kochsalzlosung, 10 Katzen) zweimal pro Woche subkutan uber 6 Wochen behandelt. Der Therapieerfolg wurde anhand des Karnofsky-Indexes fur das Allgemeinbefinden, der Auspragung der Symptome von Konjunktivitis und Stomatitis sowie durch die Bestimmung von labordiagnostischen (Hamatologie, Serumchemie), immunologischen (Lymphozytensubpopulationen, CD4\/CD8-Ratio) und Surrogatparametern (Biopterin, 7-Xanthopterin) beurteilt. Ergebnisse: Melittin fuhrte zu einer Verbesserung des Allgemeinbefindens und zu einer Abnahme der klinischen Symptome von Stomatitis und Konjunktivitis. Eine statistisch signifikante Verbesserung der Konjunktivitis ergab sich jedoch nur bei hauptsachlich mit Melittin behandelten Katzen im Vergleich zu Katzen der Plazebogruppe. Dies war vermutlich auf die verschiedenen Scores am Anfang der Studie zuruckzufuhren. Es wurde kein Anstieg der CD4+-Lymphozyten-Konzentration, des CD4\/CD8-Verhaltnisses und der Pterinkonzentrationen beobachtet. Melittin war gut vertraglich und hatte keine Nebenwirkungen. Schlussfolgerung und klinische Relevanz: Mit dieser Studie lies sich keine Wirksamkeit von Melittin nachweisen. In zukunftigen Studien konnte das Medikament aber in einer hoheren Dosierung oder uber einen langeren Behandlungszeitraum als in der vorliegenden Studie untersucht werden. Auch eine Kombination mit klassischen antiretroviralen Medikamenten ware denkbar, da fur andere Naturprodukte positive synergistische Wirkungen gezeigt wurden.<\/jats:p>","DOI":"10.15654\/tpk-150890","type":"journal-article","created":{"date-parts":[[2016,11,3]],"date-time":"2016-11-03T09:36:00Z","timestamp":1478165760000},"page":"417-423","source":"Crossref","is-referenced-by-count":6,"title":["Wirksamkeit von Melittin bei der Behandlung von Katzen mit feliner Immunschw\u00e4chevirusinfektion"],"prefix":"10.15654","volume":"44","author":[{"given":"Natalie","family":"Wilhelm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Erfle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Hartmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja D.","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2017,12,20]]},"reference":[{"key":"10.15654\/TPK-150890-1","doi-asserted-by":"crossref","first-page":"5652","DOI":"10.1128\/JVI.64.11.5652-5655.1990","volume":"64","author":"Ackley","year":"1990","journal-title":"J Virol"},{"key":"10.15654\/TPK-150890-2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2003.07.022"},{"key":"10.15654\/TPK-150890-3","unstructured":"Ammentorp-Schmidt B. Antiretrovirale Wirkung von Melittin bei der Rauscher-Leuk\u00e4mie-Infektion in vivo und in vitro. Dissertation, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen 1994"},{"key":"10.15654\/TPK-150890-4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.1988.tb13977.x"},{"key":"10.15654\/TPK-150890-5","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1128\/AAC.41.7.1521","volume":"41","author":"Boyd","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.15654\/TPK-150890-6","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1128\/AAC.43.8.1827","volume":"43","author":"Buckheit","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.15654\/TPK-150890-7","doi-asserted-by":"publisher","DOI":"10.1002\/1098-1128(200009)20:5<323::AID-MED1>3.0.CO;2-A"},{"key":"10.15654\/TPK-150890-8","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.10.4562-4569.2000"},{"key":"10.15654\/TPK-150890-9","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(88)90111-7"},{"key":"10.15654\/TPK-150890-10","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.2460\/javma.1991.199.10.1339","volume":"199","author":"Egberink","year":"1991","journal-title":"J Am Vet Med Assoc"},{"key":"10.15654\/TPK-150890-11","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.76.11.5843"},{"key":"10.15654\/TPK-150890-12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199001183220305"},{"issue":"Suppl.","key":"10.15654\/TPK-150890-13","first-page":"37","volume":"5","author":"Goldberg","year":"1989","journal-title":"Tierarztl Prax"},{"key":"10.15654\/TPK-150890-14","doi-asserted-by":"publisher","DOI":"10.1515\/bchm2.1967.348.1.37"},{"key":"10.15654\/TPK-150890-15","doi-asserted-by":"publisher","DOI":"10.1177\/1098612X11431040"},{"key":"10.15654\/TPK-150890-16","unstructured":"Hartmann K. Entwicklung eines Testsystems zur Erprobung neuer Medikamente gegen die FIV-Infektion der Katze als Modell f\u00fcr die Behandlung erworbener Immunschw\u00e4chesyndrome. Habilitation, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen 1995"},{"key":"10.15654\/TPK-150890-17","doi-asserted-by":"publisher","DOI":"10.1016\/0165-2427(92)90129-E"},{"key":"10.15654\/TPK-150890-18","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-3542(97)00030-2"},{"key":"10.15654\/TPK-150890-19","first-page":"95","volume":"3","author":"Hartmann","year":"1998","journal-title":"Eur J Med Res"},{"key":"10.15654\/TPK-150890-20","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-199802010-00004"},{"key":"10.15654\/TPK-150890-21","first-page":"438","volume":"132","author":"Hoffmann-Fezer","year":"1990","journal-title":"Schweiz Arch Tierheilkd"},{"key":"10.15654\/TPK-150890-22","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1128\/CDLI.4.1.33-42.1997","volume":"4","author":"Hofmann-Lehmann","year":"1997","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.15654\/TPK-150890-23","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2346"},{"key":"10.15654\/TPK-150890-24","doi-asserted-by":"publisher","DOI":"10.1021\/jm00093a004"},{"key":"10.15654\/TPK-150890-25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.26.12466"},{"key":"10.15654\/TPK-150890-26","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.3.664-672.2001"},{"key":"10.15654\/TPK-150890-27","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199012000-00005"},{"key":"10.15654\/TPK-150890-28","doi-asserted-by":"publisher","DOI":"10.1021\/jm00078a001"},{"key":"10.15654\/TPK-150890-29","unstructured":"Rauer M. Nachweis und Quantifizierung des Felinen Immundefizienz-Virus in nat\u00fcrlich infizierten Katzen mit Hilfe der Polymerase-Kettenreaktion. Dissertation, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen 1993"},{"key":"10.15654\/TPK-150890-30","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.1860050606"},{"key":"10.15654\/TPK-150890-31","unstructured":"Sherer R, Dutta B, Anderson R, Laudette-Aboulhab J, Kamarulzaman A, D\u2019Amico R, Paton N, Abdullah MS. A phase IB study of (+)-calanolide A in HIV-1-infected, antiretroviral therapy-naive patients. Proceedings of the 7th Conference on Retroviruses and Opportunistic Infections; 30 January-2 February 2000; San Francisco, USA; p. 171"},{"key":"10.15654\/TPK-150890-32","first-page":"114","volume":"2","author":"Taylor","year":"1989","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.15654\/TPK-150890-33","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3495(81)84719-4"},{"key":"10.15654\/TPK-150890-34","unstructured":"Wachinger M. Wirkungen von Melittin auf die HIV-1-Produktion in vitro. Ebenhausen: Langewiesche-Brandt 1994"},{"key":"10.15654\/TPK-150890-35","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-79-4-731"},{"key":"10.15654\/TPK-150890-36","unstructured":"Wachinger M, Ludvigsen A, Neumann M, Brack-Werner R, Saermark T, Erfle V. Amphipathic peptide melittin: inhibitory effects on HIV-LTR activity, HIV-RNA levels and HIV protein expression. Proceedings of the IX. International AIDS Conference; 7-11 June 1993; Berlin, Germany; p. 146"},{"key":"10.15654\/TPK-150890-37","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(92)80780-K"},{"key":"10.15654\/TPK-150890-38","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-0813.1996.tb10039.x"}],"container-title":["Tier\u00e4rztliche Praxis Ausgabe K: Kleintiere \/ Heimtiere"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.15654\/TPK-150890.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T09:54:23Z","timestamp":1718877263000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.15654\/TPK-150890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":38,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2017,12,23]]},"published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.15654\/tpk-150890","relation":{},"ISSN":["1434-1239","2567-5842"],"issn-type":[{"value":"1434-1239","type":"print"},{"value":"2567-5842","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}